Why the study?
Does silencing ANGPTL4 protect against LPS-induced acute lung injury in preclinical models?
Population
Mouse model of lipopolysaccharide-induced acute lung injury and human alveolar epithelial A549 cells
Comparison
Lentivirus-mediated short interfering RNA… vs Negative control lentivirus (NCsiRNA)
Design
Preclinical
Authors
Loading...
Supports ANGPTL4 silencing in preclinical ALI models; leaves open translation to human therapy.
Does silencing ANGPTL4 protect against LPS-induced acute lung injury in preclinical models?
Silencing ANGPTL4 protects against LPS-induced acute lung injury by regulating the SIRT1/NF-kB signaling pathway in preclinical models.
Guo et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: